Ellex acquires iScience Interventional
Ellex Medical Lasers Limited announced that it has recently acquired the canaloplasty business of US-based iScience Interventional, Inc.
Adelaide, Australia-Ellex Medical Lasers Limited announced that it has recently acquired the canaloplasty business of US-based iScience Interventional, Inc., which comprises the iTRACK 250 catheter and suture device for the treatment of mild to moderate glaucoma.
Canaloplasty is an advanced, minimally invasive procedure for the treatment of mild to moderate glaucoma. Offering significant advantages to traditional trabeculectomy, it can also be used in conjunction with existing laser and drug-based glaucoma treatments.
Clinical studies have shown canaloplasty to be as effective as surgery in lowering intraocular pressure (IOP), with the added benefit of reducing the need for ongoing glaucoma medications. It also offers a high benefit/risk ratio and is quicker to perform, taking approximately 10-25 minutes.
The business will trade as “Ellex iScience, Inc.” Production of the iTRACK 250 will continue out of the existing FDA-approved facility at Menlo Park in San Francisco, CA.
